Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on bacteriophage-based therapies. As of November 6, 2026, the company had 37,192,632 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.
Armata Pharmaceuticals reported its third quarter 2026 financial results and provided an update on its AP-SA02 Phase 3 program. The company is finalizing study designs with the FDA and has completed engineering runs at its cGMP manufacturing facility to support the upcoming pivotal trial.
“We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02. We have progressed from planning to establishing the operational infrastructure needed to execute a large, pivotal clinical study.”
Dr. Deborah Birx, Chief Executive Officer
“We believe the FDA’s recent Breakthrough Therapy designation further underscores AP-SA02’s clinical potential. We also appreciate the continued financial support of the U.S. Department of War (“DoW”), which comes at an important time as we prepare for this next critical stage of clinical development.”
Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its AP-SA02 bacteriophage candidate. This incremental funding brings the total cumulative government support for the program to $32.4 million and is intended to fund activities for a pivotal superiority study in complicated S. aureus bacteremia.